146 related articles for article (PubMed ID: 11036955)
1. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer.
Kollmannsberger C; Gerl A; Schleucher N; Beyer J; Kuczyk M; Rick O; Casper J; Sosada M; Rie C; Kanz L; Bokemeyer C
Anticancer Drugs; 2000 Aug; 11(7):535-9. PubMed ID: 11036955
[TBL] [Abstract][Full Text] [Related]
2. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Hamlin PA; Perales MA; Gerecitano J; Horwitz SM; Matasar MJ; Noy A; Palomba ML; Portlock CS; Straus DJ; Graustein T; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2013 Feb; 31(4):456-60. PubMed ID: 23248254
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Beyer J; Metzner B; Ruther U; Harstrick A; Weissbach L; Kohrmann U; Verbeek W; Schmoll HJ
Ann Oncol; 1996 Jan; 7(1):31-4. PubMed ID: 9081388
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience.
Farhat F; Culine S; Théodore C; Békradda M; Terrier-Lacombe MJ; Droz JP
Cancer; 1996 Mar; 77(6):1193-7. PubMed ID: 8635143
[TBL] [Abstract][Full Text] [Related]
8. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer.
Motzer RJ; Sheinfeld J; Mazumdar M; Bains M; Mariani T; Bacik J; Bajorin D; Bosl GJ
J Clin Oncol; 2000 Jun; 18(12):2413-8. PubMed ID: 10856101
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Bokemeyer C; Kollmannsberger C; Harstrick A; Beyer J; Gerl A; Casper J; Metzner B; Hartmann JT; Schmoll HJ; Kanz L
Int J Cancer; 1999 Dec; 83(6):848-51. PubMed ID: 10597209
[TBL] [Abstract][Full Text] [Related]
12. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V
Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA
Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816
[TBL] [Abstract][Full Text] [Related]
14. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer.
Broun ER; Nichols CR; Gize G; Cornetta K; Hromas RA; Schacht B; Einhorn LH
Cancer; 1997 Apr; 79(8):1605-10. PubMed ID: 9118046
[TBL] [Abstract][Full Text] [Related]
15. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
16. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
17. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Weidmann E; Kim SZ; Rost A; Schuppert H; Seipelt G; Hoelzer D; Mitrou PS
Ann Oncol; 2002 Aug; 13(8):1285-9. PubMed ID: 12181253
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Bokemeyer C; Gerl A; Schöffski P; Harstrick A; Niederle N; Beyer J; Casper J; Schmoll HJ; Kanz L
J Clin Oncol; 1999 Feb; 17(2):512-6. PubMed ID: 10080593
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
